0L8 Stock Overview
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Lantheus Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$74.94 |
| 52 Week High | US$114.30 |
| 52 Week Low | US$46.59 |
| Beta | 0.51 |
| 11 Month Change | -25.69% |
| 3 Month Change | -13.14% |
| 1 Year Change | 19.71% |
| 33 Year Change | 190.47% |
| 5 Year Change | 300.75% |
| Change since IPO | 1,115.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0L8 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -12.7% | -4.5% | -0.6% |
| 1Y | 19.7% | -3.2% | 9.6% |
Return vs Industry: 0L8 exceeded the German Medical Equipment industry which returned -3.8% over the past year.
Return vs Market: 0L8 exceeded the German Market which returned 7.8% over the past year.
Price Volatility
| 0L8 volatility | |
|---|---|
| 0L8 Average Weekly Movement | 7.6% |
| Medical Equipment Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0L8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0L8's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 834 | Brian Markison | www.lantheus.com |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer.
Lantheus Holdings, Inc. Fundamentals Summary
| 0L8 fundamental statistics | |
|---|---|
| Market cap | €5.27b |
| Earnings (TTM) | €406.74m |
| Revenue (TTM) | €1.42b |
13.1x
P/E Ratio3.8x
P/S RatioIs 0L8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0L8 income statement (TTM) | |
|---|---|
| Revenue | US$1.50b |
| Cost of Revenue | US$533.18m |
| Gross Profit | US$963.62m |
| Other Expenses | US$536.00m |
| Earnings | US$427.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.15 |
| Gross Margin | 64.38% |
| Net Profit Margin | 28.57% |
| Debt/Equity Ratio | 47.8% |
How did 0L8 perform over the long term?
See historical performance and comparison